Physician profile
Mark G Clarke
NPI 1346225695
$1,606.02
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $548 · 2021: $206 · 2023: $33.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.95 | 2019-2021 | |
| Lilly USA, LLC | $283.98 | 2019-2021 | |
| Pfizer INC. | $201.30 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $122.25 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.02 | 2019-2020 | |
| Amarin Pharma, INC. | $89.70 | 2020 | |
| Novo Nordisk INC | $73.75 | 2020-2021 | |
| Glaxosmithkline, LLC. | $62.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.85 | 2019 | |
| Exact Sciences Corporation | $33.37 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.02 | 2019 | |
| Allergan, INC. | $30.49 | 2020 | |
| Sanofi Pasteur INC. | $23.65 | 2020 | |
| Merck Sharp & Dohme LLC | $22.31 | 2020 | |
| Irhythm Technologies, INC. | $17.72 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.38 | 2019 | |
| Abbott Laboratories | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.